Serial Number | 97768020 |
Word Mark | RNA ACTUATOR |
Filing Date | Wednesday, January 25, 2023 |
Status | 730 - FIRST EXTENSION - GRANTED |
Status Date | Wednesday, November 6, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, March 19, 2024 |
Goods and Services | Pharmaceutical, therapeutic pharmaceuticals, and biopharmaceutical preparations and agents for the treatment of a variety of human and animal diseases and disorders, namely, autoimmune diseases and disorders, cardiovascular diseases and disorders, connective tissues diseases and disorders, dermatological diseases and disorders, enzyme deficiency diseases and disorders, gastrointestinal diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hematological diseases and disorders, immunoregulatory diseases and disorders, infectious diseases and disorders, inflammatory diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, muscular diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, oncological diseases and disorders, ophthalmological diseases and disorders, rare diseases and disorders, renal diseases and disorders, reproductive disease and disorders, and respiratory diseases and disorders; nucleic acid-based therapeutic pharmaceuticals and therapeutic agents for the treatment of a variety of human and animal diseases and disorders, namely, autoimmune diseases and disorders, cardiovascular diseases and disorders, connective tissues diseases and disorders, dermatological diseases and disorders, enzyme deficiency diseases and disorders, gastrointestinal diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hematological diseases and disorders, immunoregulatory diseases and disorders, infectious diseases and disorders, inflammatory diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, muscular diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, oncological diseases and disorders, ophthalmological diseases and disorders, rare diseases and disorders, renal diseases and disorders, reproductive disease and disorders, and respiratory diseases and disorders; chemicals for use in therapeutic product development and manufacturing processes in the medical field |
Goods and Services | Biological and chemical agents, namely, chemical preparations for scientific and research use; synthetic nucleic acids other than for medical or veterinary purposes; chemically modified nucleic acids, other than for medical or veterinary purposes; chemicals for use in biotherapeutics in the biochemical and chemical industries and excluding medical and veterinary purpose; biological preparations for use in industry and science; chemical agents, namely, chemical preparations for analyses in laboratories, other than for medical or veterinary purposes |
NOT AVAILABLE | "RNA" |
Goods and Services | Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of a variety of human and animal diseases and disorders, namely, autoimmune diseases and disorders, cardiovascular diseases and disorders, connective tissues diseases and disorders, dermatological diseases and disorders, enzyme deficiency diseases and disorders, gastrointestinal diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hematological diseases and disorders, immunoregulatory diseases and disorders, infectious diseases and disorders, inflammatory diseases and disorders, hepatic diseases and disorders, metabolic diseases and disorders, muscular diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, oncological diseases and disorders, ophthalmological diseases and disorders, rare diseases and disorders, renal diseases and disorders, reproductive disease and disorders, and respiratory diseases and disorders; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and drug discovery services; pharmaceutical research and analysis services using machine learning analytics relating to pharmaceutical drug development; scientific research, pharmaceutical research, medical research, technical consultation, and product development for others in the field of biotechnology and development of pharmaceutical, therapeutic, and biopharmaceutical preparations and agents |
International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
US Class Codes | 001, 005, 006, 010, 026, 046 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, February 14, 2023 |
Primary Code | 001 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, February 14, 2023 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, February 14, 2023 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | CAMP4 Therapeutics Corporation |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 03 - Corporation |
Address | Cambridge, MA 02139 |
Party Name | CAMP4 Therapeutics Corporation |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Cambridge, MA 02139 |
Event Date | Event Description |
Saturday, January 28, 2023 | NEW APPLICATION ENTERED |
Tuesday, February 14, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Monday, October 23, 2023 | ASSIGNED TO EXAMINER |
Wednesday, November 15, 2023 | NON-FINAL ACTION WRITTEN |
Wednesday, November 15, 2023 | NON-FINAL ACTION E-MAILED |
Wednesday, November 15, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Tuesday, February 6, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Tuesday, February 6, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Wednesday, February 7, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Tuesday, February 13, 2024 | EXAMINERS AMENDMENT -WRITTEN |
Tuesday, February 13, 2024 | EXAMINERS AMENDMENT E-MAILED |
Tuesday, February 13, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
Tuesday, February 13, 2024 | EXAMINER'S AMENDMENT ENTERED |
Tuesday, February 13, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Wednesday, February 28, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Wednesday, February 28, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, March 19, 2024 | PUBLISHED FOR OPPOSITION |
Tuesday, March 19, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, May 14, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Wednesday, November 6, 2024 | SOU TEAS EXTENSION RECEIVED |
Wednesday, November 6, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Wednesday, November 6, 2024 | SOU EXTENSION 1 FILED |
Wednesday, November 6, 2024 | SOU EXTENSION 1 GRANTED |